Literature DB >> 11544434

Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

G Socié1, P Loiseau, R Tamouza, A Janin, M Busson, E Gluckman, D Charron.   

Abstract

BACKGROUND: Graft-versus-host disease is the main complication of hematopoietic stem cell transplantation. Recently, pro- and anti-inflammatory cytokines and mismatches of minor histocompatibility antigens between HLA-identical sibling donor/recipient pairs have been implicated in the development of acute graft-versus-host disease. It is not known, however, whether these factors are independent of other clinically recognized risk factors such as age and disease stage.
METHODS: In this study, we searched for risk factors of acute graft-versus-host disease using multivariate Cox regression analysis in 100 consecutive patients who underwent allogeneic stem cell transplantation from an HLA-identical sibling donor. Eight polymorphisms from five different cytokine genes were studied (tumor necrosis factor alpha, tumor necrosis factor beta, interleukin (IL) 6, IL-10, and interferon gamma). Mismatches for the minor histocompatibility antigen HA-1 were searched in HLA-A*0201 individuals. In addition to these new risk factors, patient, donor, disease, and transplant risk factors were analyzed by multivariate analysis using the Cox proportional hazards model.
RESULTS: Acute graft-versus-host disease was independently associated with IL-10 gene polymorphisms both from the recipient (relative risk=7.9, P<0.0001) and the donor (relative risk=3.5, P=0.02), a donor's positive serology for cytomegalovirus, and HA-1 mismatches in HLA-A*0201 individuals (relative risk=2.8, P=0.05). Chronic graft-versus-host disease was independently associated with IL-6 gene polymorphism from the recipient (relative risk=4.2, P=0.02), older age (relative risk=2.5, P=0.0009), and previous acute graft-versus-host disease (relative risk=9.7, P=0.003).
CONCLUSION: In addition to previously described clinical risk factors, genetic risk factors are independently associated with the risk of developing graft-versus-host disease and may, thus, be considered for the selection of the donor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544434     DOI: 10.1097/00007890-200108270-00024

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  42 in total

Review 1.  Evaluation of published single nucleotide polymorphisms associated with acute GVHD.

Authors:  Jason W Chien; Xinyi Cindy Zhang; Wenhong Fan; Hongwei Wang; Lue Ping Zhao; Paul J Martin; Barry E Storer; Michael Boeckh; Edus H Warren; John A Hansen
Journal:  Blood       Date:  2012-01-26       Impact factor: 22.113

2.  Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.

Authors:  Kailin Xu; Chaohong Li; Xiuying Pan; Bing Du
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 3.  Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality.

Authors:  John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 4.  Genetics of graft-versus-host disease: the major histocompatibility complex.

Authors:  Effie W Petersdorf
Journal:  Blood Rev       Date:  2012-11-20       Impact factor: 8.250

5.  Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor.

Authors:  Ming-Tseh Lin; Barry Storer; Paul J Martin; Li-Hui Tseng; Bryan Grogan; Pei-Jer Chen; Lue P Zhao; John A Hansen
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

Review 6.  Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes.

Authors:  John A Hansen; Effie W Petersdorf; Ming-Tseh Lin; Steven Wang; Jason W Chien; Barry Storer; Paul J Martin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

7.  Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.

Authors:  Paul J Martin; Wenhong Fan; Barry E Storer; David M Levine; Lue Ping Zhao; Edus H Warren; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Michael Boeckh; Sangeeta Hingorani; Li Yan; Qiang Hu; Leah Preus; Song Liu; Stephen Spellman; Xiaochun Zhu; Marcelo Pasquini; Philip McCarthy; Daniel Stram; Xin Sheng; Loreall Pooler; Christopher A Haiman; Lara Sucheston-Campbell; Theresa Hahn; John A Hansen
Journal:  Blood       Date:  2016-10-06       Impact factor: 22.113

8.  IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation.

Authors:  Li-Hui Tseng; Barry Storer; Effie Petersdorf; Ming-Tseh Lin; Jason W Chien; Bryan M Grogan; Mari Malkki; Pei-Jer Chen; Lue P Zhao; Paul J Martin; John A Hansen
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

9.  Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.

Authors:  In-Wha Kim; Hwi-yeol Yun; Boyoon Choi; Nayoung Han; Myeong Gyu Kim; Seonyang Park; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

10.  Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease.

Authors:  Xiao Chen; Rupali Das; Richard Komorowski; Amy Beres; Martin J Hessner; Masahiko Mihara; William R Drobyski
Journal:  Blood       Date:  2009-06-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.